Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Korea University Industry and Academic Collaboration Foundation

Korea University Industry and Academic Collaboration Foundation Patent applications
Patent application numberTitlePublished
20100137260 COMPOUND FOR INHIBITING TRPV3 FUNCTION AND USE THEREOF - The present invention relates to a TRPV3 (transient receptor potential vanilloid 3) activity inhibitor, more precisely to a method for inhibiting TRPV3 activity including the step of treating isopentenyl pyrophosphate and a method for treating skin disease containing the step of administering isopentenyl pyrophosphate to a subject with skin disease or applying the same on the skin of the subject. Isopentenyl pyrophosphate of the present invention controls increase of sensory cell reactivity to current or migration and proliferation of skin cells induced by TRPV3, so that it can be effectively used for the development of a pain reliever or a therapeutic agent for skin disease.06-03-2010
20100137259COMPOUND FOR INHIBITING TRPA1 FUNCTION AND USE THEREOF - The present invention relates to a TRPA1 activation inhibitor, more precisely a TRPA1 activity inhibitor containing isopentenyl pyrophosphate and a method for inhibiting pain containing the step of administering isopentenyl pyrophosphate to a subject. Isopentenyl pyrophosphate of the present invention can regulate pain caused by TRPA1, so that it can be effectively used for the development of a pain inhibitor which is effective but has less side effects.06-03-2010
20100136533COMPOUND CONTAINING FARNESYL DIPHOSPHATE FOR MODULATING TRPV3 FUNCTION AND USE THEREOF - The present invention relates to a method for activating TRPV3 (transient receptor potential vanilloid 3) using FPP (farnesyl diphosphate) and a method for screening a TRPV3 activity inhibitor. FPP of the present invention has TRPV3 specific activity and therefore it can be effectively used for the study on TRPV3 mechanism and functions and for the development of a TRPV3 based pain reliever.06-03-2010